Clinical trials must be more inclusive because the evidence they produce has been built on a dangerously narrow slice of the population. When a new dementia medication is tested almost exclusively on white, college-educated men in their sixties, we have no reliable way to know whether that drug will work equally well—or safely—for Black women in their seventies, Hispanic men with limited education, or people whose caregiving responsibilities make participation nearly impossible. The medications that ultimately reach patients with dementia, Alzheimer’s disease, and other cognitive conditions are approved based on trial results that may not represent the very people who need them most. The consequences are measurable. A 2022 analysis found that participants in dementia-related clinical trials were 82% white, while the general population receiving dementia diagnoses is far more diverse.
This exclusion means that medications approved based on those trials carry hidden assumptions about who they work for and who experiences side effects. A drug that appears safe in a homogeneous trial population can interact differently with the bodies and medication regimens of people with different genetic backgrounds, metabolic rates, or comorbid conditions. Inclusive clinical trials are not a matter of fairness alone, though that matters deeply. They are a scientific and medical necessity. When trial data fails to represent the actual population that will use a drug, the resulting treatment landscape becomes less effective and more unpredictable for everyone.
Table of Contents
- Who Gets Left Behind in Clinical Trial Enrollment?
- How Genetic and Biological Differences Affect Treatment Response
- Caregiving Responsibilities and Structural Barriers to Participation
- What Inclusive Trial Design Actually Requires
- The Silent Dangers of Exclusionary Trial Design
- How Dementia Disproportionately Affects Understudied Populations
- The Gap Between Trial Enrollment Standards and Real-World Patient Populations
- Frequently Asked Questions
Who Gets Left Behind in Clinical Trial Enrollment?
Dementia clinical trials have consistently excluded or severely underrepresented older adults with mild cognitive impairment or early dementia—the very population most likely to benefit from preventive or early-stage interventions. Trial protocols often demand that participants have no cognitive impairment at all, or impose strict memory test cutoffs that eliminate anyone with detectable decline. This creates a perverse situation: people whose cognition is still intact enough to consent and participate are enrolled, while people with actual dementia are screened out. The logic is convenient for researchers—cognitively intact participants are easier to follow and more likely to complete the study—but it divorces the trial from its real-world purpose. Women are also systematically underenrolled in many dementia trials, despite comprising the majority of people living with Alzheimer’s disease and related conditions.
Hormonal differences, different presentations of cognitive symptoms, and distinct patterns of comorbidities in aging women mean that trial data skewed toward men simply does not capture the full picture. When a woman enters a neurologist’s office with memory loss and is prescribed a medication tested on men, that prescription is an educated guess, not an evidence-based certainty. Racial and ethnic minorities face both structural and interpersonal barriers to trial participation. Historically exploitative medical research—including the Tuskegee syphilis study, forced sterilization programs, and ongoing disparities in pain management—has created legitimate mistrust of medical research within Black, Latino, Native American, and other marginalized communities. This isn’t paranoia; it’s accurate historical memory. When trial sites located in affluent, predominantly white neighborhoods offer enrollment, they are not reaching the people whose health outcomes have historically been worst served by medicine.
How Genetic and Biological Differences Affect Treatment Response
Clinical trial participants who are predominantly of European ancestry have inadvertently shaped medication dosing, efficacy predictions, and safety thresholds for everyone else. Genetic variation affecting drug metabolism, enzyme function, and transport protein efficiency can be significant between populations. The APOE4 gene variant, which significantly increases Alzheimer’s disease risk, shows different frequencies across ethnic groups—yet many trials have not tracked this variation or analyzed outcomes separately by genotype and ancestry. This is not theoretical. A study published in Alzheimer’s and dementia found that medications effective for cognitive decline in one population showed diminished benefit in another, with differences partially explained by genetic variation in drug-metabolizing enzymes and by differences in how disease progresses across populations.
Women of African descent, for example, tend to have higher rates of vascular contributions to cognitive impairment alongside Alzheimer’s pathology, which changes the treatment calculus entirely. A trial that enrolled only people with “pure” Alzheimer’s pathology misses this complexity and produces incomplete guidance for the real world, where most people have mixed pathologies. The limitation here is substantial: many pharmaceutical companies argue that including more genetic and ethnic diversity would make trials more expensive, longer, and harder to recruit for—all true. But the alternative is knowingly designing research that will underestimate side effects or overestimate efficacy in large segments of the eventual patient population. That is not a scientific choice; it is a business choice.
Caregiving Responsibilities and Structural Barriers to Participation
A person with early-stage dementia rarely participates in a clinical trial alone. They participate as part of a dyad—often with a spouse, adult child, or paid caregiver. Yet trial protocols frequently impose eligibility criteria that make participation logistically impossible for people with caregiving responsibilities. Trials might require monthly visits to a research site hours away, or demand that a caregiver attend every appointment. For a working adult child already struggling to balance eldercare with employment, or for a spouse who is themselves aging or managing health conditions, this is an absolute barrier. The demographics of unpaid caregiving in America are heavily female and disproportionately represent people of color and immigrants.
When trial sites do not account for caregiving loads, transportation needs, or language barriers, they are systematically excluding the exact populations that trial inclusion criteria claim to target. A trial in an urban research hospital corridor may require participants to travel for each visit; rural participants, who are on average older and have fewer local specialists, face exponentially higher barriers. An elderly person in a rural area with no family living nearby may be cognitively perfect for the trial but practically unable to participate. Some trial sites have begun addressing this by offering home visits, virtual assessments, or transportation assistance. These accommodations cost more but produce more representative data. Other sites have not, and continue enrolling the participants who can most easily clear logistical hurdles rather than the people who most need the treatment being tested.
What Inclusive Trial Design Actually Requires
Inclusive clinical trials demand intentional design changes, not just good intentions. This means setting eligibility criteria that do not arbitrarily exclude people with mild cognitive impairment, adjusting cognitive test cutoffs to match clinical reality, and allowing people with comorbid conditions—hypertension, diabetes, kidney disease—to participate as long as those conditions are stable. Most people with dementia have other chronic illnesses; trials that exclude them are studying an imaginary population. It means actively recruiting from diverse communities through trusted local organizations, offering culturally appropriate materials and interpretation services, and paying participants adequately to offset the real costs of time and travel. A $25 gift card for four hours of appointments and travel time is insulting and confirms the message that participants’ time is less valuable than the researchers’ convenience. Some trial sites now offer $50 to $100 per visit, transportation vouchers, and flexible scheduling.
These trials recruit and retain more diverse participants. The tradeoff is that trial costs increase and sample sizes must sometimes shrink to accommodate the higher per-participant expense—but the data is more useful. Inclusive design also means analyzing outcomes not just for the full group but broken down by race, ethnicity, sex, age, and other relevant variables. If a medication works differently in different populations, the trial should reveal that, not hide it in aggregate averages. This requires statistical planning from the beginning and an unwillingness to dismiss subgroup differences as noise. Some pharmaceutical companies resist this transparency, arguing that it complicates the story of a drug’s efficacy. But a complicated story that is true is better than a simple story that is incomplete.
The Silent Dangers of Exclusionary Trial Design
When trials exclude people with actual dementia from early cognitive decline trials, they produce medications that have never been tested in the target population. A drug shown to slow cognitive decline in cognitively normal older adults might work very differently—or not at all—in someone whose neurons are already degenerating. We do not know because the trial never asked. This is not a minor methodological quibble; it is a fundamental mismatch between what is tested and what is prescribed. There is also a real danger of harm that goes undetected. Women metabolize many drugs differently than men, in part because of body composition, hormonal factors, and differences in enzyme expression.
If a trial enrolled only men, an effective dose for a woman might produce excessive side effects, or a “safe” dose might prove inadequate. For dementia medications, where the therapeutic window is often narrow and side effects like falls or cardiac arrhythmias can be life-altering or fatal in an older adult, this is not a minor concern. A drug approved based on trials that did not adequately represent women is a drug whose safety profile for women remains partially unknown. The warning that trial exclusions generate is also hidden from public awareness. If patients knew that the medication being prescribed to them had been tested primarily on people unlike them, they might ask harder questions or demand more frequent monitoring. Instead, marketing materials and clinical guidance present medication efficacy as universal, masking the fact that effectiveness estimates rest on narrow populations.
How Dementia Disproportionately Affects Understudied Populations
Dementia does not strike randomly across populations. Rates of Alzheimer’s disease and related dementias are highest among the oldest old, and life expectancy varies by race and socioeconomic status. Black Americans develop dementia at higher rates than white Americans and develop it earlier—yet they remain underrepresented in trials testing preventive interventions that could help them most.
Hispanic and Latino older adults show high dementia rates and have very limited representation in English-language trials, creating a language barrier to participation that trial sites often do not address. Women outnumber men among people living with Alzheimer’s disease by a significant margin, in part due to longer life expectancy but also possibly due to different vascular and hormonal risk factors. Yet many dementia prevention trials enroll men and women at roughly equal rates, meaning women remain underrepresented relative to disease burden. A preventive trial testing a medication that has never been adequately studied in women cannot confidently say whether that prevention strategy works for the population most at risk.
The Gap Between Trial Enrollment Standards and Real-World Patient Populations
The patients who walk into memory clinics and neurology offices do not look like trial cohorts. They have multiple illnesses, take numerous medications, live alone or with family members whose own health is declining, and come from varied educational and socioeconomic backgrounds. They speak different languages, have different trust relationships with medical institutions, and have different resources for participating in research. Yet trial inclusion and exclusion criteria remain largely designed around convenience and the false belief that controlling variables through narrow recruitment produces “cleaner” science.
Some of the most rigorous recent dementia prevention trials have begun to challenge this assumption. The FINGER trial in Finland and its adaptations in other countries have intentionally enrolled diverse older adults, allowed comorbidities, and tracked outcomes separately by demographic group. The result has been data that is actually useful to real clinicians treating real patients, not data that applies cleanly only to the narrow slice of the population the trial enrolled. More trials need to follow this model, accepting that inclusive recruitment makes trials somewhat messier but makes the resulting evidence more honest and more useful.
Frequently Asked Questions
Why do researchers exclude people with dementia from dementia trials?
Researchers have historically excluded or limited enrollment of people with cognitive impairment because they are perceived as harder to recruit and retain, less able to provide informed consent, and more likely to have comorbidities that complicate study design. These exclusions make trials administratively simpler but scientifically less representative.
Does genetic ancestry really affect how dementia medications work?
Yes. Differences in drug-metabolizing enzymes, transport proteins, and disease progression patterns exist across ancestral groups. When trials do not include these differences, the resulting medications may work differently or carry different side effect profiles than clinical guidelines suggest.
How much more does it cost to run an inclusive trial?
Inclusive trials typically cost 15 to 30 percent more per participant due to transportation assistance, interpretation services, flexible scheduling, and community outreach. However, a smaller diverse sample often produces more useful data than a larger homogeneous sample, which can offset increased per-participant costs.
Are there requirements for clinical trial diversity?
The FDA and NIH now require diversity in trial recruitment and analysis of outcomes by demographic subgroups for many study types. However, enforcement is inconsistent, and many trials still rely on convenience sampling rather than active diverse recruitment.
What can caregivers do if they want a family member with dementia to participate in research?
Ask potential trial sites directly whether they allow people with cognitive impairment, offer flexible scheduling, provide transportation, and have staff trained in dementia communication. Ask whether outcomes will be analyzed separately by race, sex, and other demographics.
Why do some people mistrust medical research?
Historically marginalized communities have experienced exploitation and harm in medical research, from unethical studies to unequal care. This creates legitimate skepticism about new research participation, which trial sites must acknowledge and address through transparency and community partnership rather than by ignoring it.
